bluuebunny/crossref_metadata_2025_split huggingface dataset:
Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: A pilot study
Authors: Knopf Andreas , Lahmer Tobias , Chaker Adam , Stark Thomas , Hofauer Benedikt , Pickhard Anja , Thürmel Klaus , Bas Murat 
Published: June 2012

AbstractBackgroundTo suggest treatment modalities with respect to the specific requirements of head and neck sarcoidosis.MethodsHead and neck sarcoidosis was diagnosed in 31 patients. Treatment regimes comprised wait and see, corticosteroid‐pulse, stable‐dose corticosteroids, or adalimumab.ResultsIn all, 21 patients had isolated head and neck sarcoidosis and a further 8 patients showed concomitant pulmonary sarcoidosis. Two patients with pulmonary sarcoidosis developed subsequent head and neck manifestation. Most patients with isolated head and neck sarcoidosis did not receive systemic therapy. None exhibited relapsing disease. Three patients with head and neck manifestation underwent corticosteroid pulse. Complete remission (CR) was detected for all after 5 months. Six patients were treated with stable‐dose corticosteroids. Five of 6 showed CR after 12 months and 1 of 6 patients partial remission (PR) after 24 months. Five of 6 patients exhibited relapses. Two patients underwent adalimumab therapy and showed PR after 65 or CR after 26 months, respectively.ConclusionsMost patients with head and neck sarcoidosis did not require systemic therapy. We suggest corticosteroid‐pulse therapy for patients with severe head and neck manifestation. Adalimumab might be potent for nonresponder. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
Clinical determinants of weight loss in patients receiving radiation and chemoirradiation for head and neck cancer: A prospective longitudinal view
Authors: Kubrak Catherine , Olson Kärin , Jha Naresh , Scrimger Rufus , Parliament Matthew , McCargar Linda , Koski Sheryl , Baracos Vickie E. 
Published: June 2012

AbstractBackgroundWe aimed to determine the effects of systemic inflammation and symptoms of head and neck cancer patients on dietary intake and weight in relation to mode of treatment.MethodsIn all, 38 orally fed patients had intake, weight, C‐reactive protein (CRP), and symptoms prospectively assessed at baseline, post‐treatment, and follow‐up.ResultsIntake/weight declined and CRP increased substantially in chemoirradiation patients (−11.4 ± 5.2 kg, −1214 kcal/day, 23.4 ± 24.9 mg/L; p < .05) versus radiotherapy patients (−3.5 ± 4.8 kg, −483 kcal/day, 8.3 ± 13.9 mg/L) during posttreatment (repeated‐measures ANOVA). Multivariate generalized estimating equations modeling identified reduced swallowing capacity was a key predictor of energy intake in both treatment groups (p < .001); multiple symptoms experienced by radiotherapy/chemoirradiation patients were significant predictors of weight loss; additionally, in chemoirradiation patients, CRP was an independent predictor of weight loss (p < .001).ConclusionsTreatment of symptoms and systemic inflammation are important clinical targets to manage weight loss in patients with head and neck cancer, especially those treated with chemoirradiation. Head Neck, 2013
Prognostic factors for supraglottic laryngeal carcinoma: Importance of the unfit patient
Authors: Smee Robert I. , De–loyde Katie J. , Broadley Kathryn , Williams Janet R. 
Published: June 2012

AbstractBackgroundThe purpose of this study was to define prognostic factors for supraglottic laryngeal cancer that may influence management.MethodsThis ethics‐approved study captured information on patients who presented with supraglottic laryngeal cancer between 1967 and 2008. Endpoints were local/ultimate failure and cancer‐specific survival (CSS). Analysis was performed using chi‐square, Fisher exact test, and logistic regression. Kaplan–Meier and Cox regression analysis were used to describe time‐to‐event data.ResultsThree hundred sixty‐nine patients were analyzed. Two hundred seventeen patients received radiotherapy, 30 were treated with surgery, and 122 were treated with radiotherapy and surgery. The 5‐year ultimate local control and CSS rates were 79.5% and 62.8%. Treatment type was a univariate predictor for outcome; however, it was not an independent predictor for ultimate local control or CSS.ConclusionsThis study highlights the fact that by documenting information it is possible to define prognostic factors. It also shows the importance of adjusting for clinical predictors such as patients being unfit for surgery. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
Fiber‐optic endoscopic evaluation of swallowing (FEES): Predictor of swallowing‐related complications in the head and neck cancer population
Authors: Deutschmann Michael W. , McDonough Alanna , Dort Joseph C. , Dort Erika , Nakoneshny Steve , Matthews T. Wayne 
Published: June 2012

AbstractBackgroundThe treatment of head and neck cancer is associated with significant dysphagia and morbidity. Prescribing a safe oral diet in this population is challenging.MethodsData from 116 consecutive patients having 189 fiber‐optic endoscopic evaluation of swallowing (FEES) examinations over a 3‐year period were analyzed. All patients had been treated for head and neck cancer and subsequently were assessed by FEES. The primary outcome was the incidence of swallowing‐related adverse events resulting from the FEES‐based dietary recommendations.ResultsThere were 10 episodes of aspiration pneumonia, 4 episodes of airway obstruction, 3 unanticipated insertions of gastrostomy tubes, and 2 unexplained deaths within the study period. The overall rate of adverse events was 10.1%. The only statistically significant predictor of adverse events was the Rosenbek score (p = .03).ConclusionsOur experience is that FEES guides appropriate and safe diet recommendations in this population. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
Nomogram for selecting thyroid nodules for ultrasound‐guided fine‐needle aspiration biopsy based on a quantification of risk of malignancy
Authors: Nixon Iain J. , Ganly Ian , Hann Lucy E. , Yu Changhong , Palmer Frank L. , Whitcher Monica M. , Shah Jatin P. , Shaha Ashok , Kattan Michael W. , Patel Snehal G. 
Published: June 2012

AbstractBackgroundOur aim through this study was to develop a statistical tool to quantify risk of malignancy in thyroid nodules based on clinical, biochemical, and ultrasound features, which could be used to select which nodules require ultrasound‐guided fine‐needle aspiration.MethodsClinical records, biochemical profiles, pathology reports, and ultrasound images were reviewed. Multivariate logistic regression was used to rank variables in their ability to predict malignancy.ResultsIn all, 190 nodules were reviewed. The final diagnoses were papillary carcinoma in 105 patients (66%), other carcinoma in 8 patients (5%), and benign thyroid pathology in 45 patients (29%). After exclusions, 182 nodules remained for analysis on a per nodule basis. The 8 variables with highest predictive value were: age; thyroid‐stimulating hormone; and ultrasound size, shape, echo texture, calcification, margin, and vascularity. The nomogram had a concordance index of 75%.ConclusionWe produced a nomogram able to accurately predict the need to perform ultrasound‐guided fine‐needle aspiration on a thyroid nodule based on biochemical, clinical, and ultrasound features. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
Comparison of national and regional sediment quality guidelines for classifying sediment toxicity in California
Authors: Bay Steven M , Ritter Kerry J , Vidal-Dorsch Doris E , Field L Jay 
Published: June 2012

Abstract
A number of sediment quality guidelines (SQGs) have been developed for relating chemical concentrations in sediment to their potential for effects on benthic macroinvertebrates, but there have been few studies evaluating the relative effectiveness of different SQG approaches. Here we apply 6 empirical SQG approaches to assess how well they predict toxicity in California sediments. Four of the SQG approaches were nationally derived indices that were established in previous studies: effects range median (ERM), logistic regression model (LRM), sediment quality guideline quotient 1 (SQGQ1), and Consensus. Two approaches were variations of nationally derived approaches that were recalibrated to California-specific data (CA LRM and CA ERM). Each SQG approach was applied to a standardized set of matched chemistry and toxicity data for California and an index of the aggregate magnitude of contamination (e.g., mean SQG quotient or maximum probability of toxicity) was calculated. A set of 3 thresholds for classification of the results into 4 categories of predicted toxicity was established for each SQG approach using a statistical optimization procedure. The performance of each SQG approach was evaluated in terms of correlation and categorical classification accuracy. Each SQG index had a significant, but low, correlation with toxicity and was able to correctly classify the level of toxicity for up to 40% of samples. The CA LRM had the best overall performance, but the magnitude of differences in classification accuracy among the SQG approaches was relatively small. Recalibration of the indices using California data improved performance of the LRM, but not the ERM. The LRM approach is more amenable to revision than other national SQGs, which is a desirable attribute for use in programs where the ability to incorporate new information or chemicals of concern is important. The use of a consistent threshold development approach appeared to be a more important factor than type of SQG approach in determining SQG performance. The relatively small change in classification accuracy obtained with regional calibration of these SQG approaches suggests that further calibration and normalization efforts are likely to have limited success in improving classification accuracy associated with biological effects. Fundamental changes to both SQG components and conceptual approach are needed to obtain substantial improvements in performance. These changes include updating the guideline values to include current use pesticides, as well as developing improved approaches that account for changes in contaminant bioavailability. Integr Environ Assess Manag 2012; 8: 597–609. © 2012 SETAC
Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer
Authors: Yokoyama Takuhei , Enomoto Takayuki , Serada Satoshi , Morimoto Akiko , Matsuzaki Shinya , Ueda Yutaka , Yoshino Kiyoshi , Fujita Masami , Kyo Satoru , Iwahori Kota , Fujimoto Minoru , Kimura Tadashi , Naka Tetsuji 
Published: June 2012

AbstractThis report utilizes a novel proteomic method for discovering potential therapeutic targets in endometrial cancer. We used a biotinylation‐based approach for cell‐surface protein enrichment combined with isobaric tags for relative and absolute quantitation (iTRAQ) technology using nano liquid chromatography–tandem mass spectrometry analysis to identify specifically overexpressed proteins in endometrial cancer cells compared with normal endometrial cells. We identified a total of 272 proteins, including 11 plasma membrane proteins, whose expression increased more than twofold in at least four of seven endometrial cancer cell lines compared with a normal endometrial cell line. Overexpression of bone marrow stromal antigen 2 (BST2) was detected and the observation was supported by immunohistochemical analysis using clinical samples. The expression of BST2 was more characteristic of 118 endometrial cancer tissues compared with 59 normal endometrial tissues (p < 0.0001). The therapeutic effect of an anti‐BST2 antibody was studied both in vitro and in vivo. An anti‐BST2 monoclonal antibody showed in vitro cytotoxicity in BST2‐positive endometrial cancer cells via antibody‐dependent cell‐mediated cytotoxicity and complement‐dependent cytotoxicity. In an in vivo xenograft model, anti‐BST2 antibody treatment significantly inhibited tumor growth of BST2‐positive endometrial cancer cells in an NK cell‐dependent manner. The anti‐BST2 antibody had a potent antitumor effect against endometrial cancer both in vitro and in vivo, indicating a strong potential for clinical use of anti‐BST2 antibody for endometrial cancer treatment. The combination of biotinylation‐based enrichment of cell‐surface proteins and iTRAQ analysis should be a useful screening method for future discovery of potential therapeutic targets.
Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women
Authors: Hosaka Masayoshi , Fujita Hiromasa , Hanley Sharon JB , Sasaki Takayuki , Shirakawa Yozo , Abiko Mitsuharu , Kudo Masataka , Kaneuchi Masanori , Watari Hidemichi , Kikuchi Kohkichi , Sakuragi Noriaki 
Published: June 2012

AbstractWe examined incidence probabilities of cervical intraepithelial neoplasia 3 (CIN3) or more severe lesions (CIN3+) in 1,467 adult Japanese women with abnormal cytology in relation to seven common human papillomavirus (HPV) infections (16/18/31/33/35/52/58) between April 2000 and March 2008. Sixty‐seven patients with multiple HPV infection were excluded from the risk factor analysis. Incidence of CIN3+ in 1,400 patients including 68 with ASCUS, 969 with low grade squamous intraepithelial lesion (LSIL), 132 with HSIL without histology‐proven CIN2 (HSIL/CIN2(−)) and 231 with HSIL with histology‐proven CIN2 (HSIL/CIN2(+)) was investigated. In both high grade squamous intraepithelial lesion (HSIL)/CIN2(−) and HSIL/CIN2(+), HPV16/18/33 was associated with a significantly earlier and higher incidence of CIN3+ than HPV31/35/52/58 (p = 0.049 and p = 0.0060, respectively). This association was also observed in LSIL (p = 0.0002). The 1‐year cumulative incidence rate (CIR) of CIN3+ in HSIL/CIN2(−) and HSIL/CIN2(+) according to HPV genotypes (16/18/33 vs. 31/35/52/58) were 27.1% vs. 7.5% and 46.6% vs. 19.2%, respectively. In contrast, progression of HSIL/CIN2(+) to CIN3+ was infrequent when HPV DNA was undetected: 0% of 1‐year CIR and 8.1% of 5‐year CIR. All cervical cancer occurred in HSIL cases of seven high‐risk HPVs (11/198) but not in cases of other HPV or undetectable/negative‐HPV (0/165) (p = 0.0013). In conclusion, incidence of CIN3+ depends on HPV genotypes, severity of cytological abnormalities and histology of CIN2. HSIL/CIN2(+) associated with HPV16/18/33 may justify early therapeutic intervention, while HSIL/CIN2(−) harboring these HPV genotypes needs close observation to detect incidence of CIN3+. A therapeutic intervention is not indicated for CIN2 without HPV DNA.
Prognostic significance of cyclooxygenase‐2 in cervical cancer: A meta‐analysis
Authors: Huang Miaoling , Chen Qing , Xiao Jianpeng , Liu Changhao , Zhao Xiaomiao 
Published: June 2012

AbstractPublished data on the prognostic value of cyclooxygenase‐2 (COX‐2) overexpression in cervical cancer are conflicting and heterogeneous. We performed a meta‐analysis to more precisely estimate its prognostic significance. The pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate the effects. Twenty‐three studies with 1,477 cervical cancer patients were selected to evaluate the association between COX‐2 and overall survival (OS), disease‐free survival (DFS), response to chemoradiation (RC) and clinicopathological parameters. High COX‐2 expression predicted poor OS (HR: 2.53, 95% CI: 1.54–4.18), DFS (HR: 2.41, 95% CI: 1.58–3.69) and RC (OR: 3.03, 95% CI: 1.97–4.64). Subgroup analyses showed that COX‐2 overexpression was related significantly with poor OS in patients treated by chemoradiation or surgery, and in patients with squamous cell carcinoma, respectively. Besides, COX‐2 overexpression was related significantly with poor DFS in chemoradiation subgroup. Furthermore, COX‐2 overexpression was associated with poor RC in patients who received “FP” regimen or “P” regimen. Additionally, there were significant associations between COX‐2 expression and all clinicopathological parameters except tumor grade. The pooled ORs (95% CI) were as follows: 1.49 (1.09–2.04) for age, 1.77 (1.22–2.56) for lymph node metastasis, 1.04 (0.74–1.47) for tumor grade, 1.71 (1.12–2.64) for tumor size, 2.38 (1.28–4.45) for FIGO stage, 3.96 (2.32–6.77) for histological type, 2.45(1.10–5.42) for parametrical involvement. This meta‐analysis indicated that COX‐2 overexpression might be an unfavorable prognostic and a chemoradiation resistance predictive factor for cervical cancer; it could potentially help to stratify patients further in clinical treatment.
Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage
Authors: Xi Long Fu , Schiffman Mark , Koutsky Laura A. , He Zhonghu , Winer Rachel L. , Hulbert Ayaka , Lee Shu‐Kuang , Ke Yang , Kiviat Nancy B. 
Published: June 2012

AbstractVariants of human papillomavirus (HPV) type 31 have been shown to be related both to risk of cervical lesions and racial composition of a population. It is largely undetermined whether variants differ in their likelihood of persistence. Study subjects were women who participated in the ASCUS‐LSIL Triage Study and who had a newly detected HPV31 infection during a two‐year follow‐up with six‐month intervals. HPV31 isolates were characterized by sequencing and assigned to one of three variant lineages. Loss of the newly detected HPV31 infection was detected in 76 (47.5%) of the 160 women (32/67 with A variants, 16/27 with B variants and 28/66 with C variants). The adjusted hazard ratio associating loss of the infection was 1.2 (95% CI, 0.7–2.1) for women with A variants and 2.1 (95% CI, 1.2–3.5) for women with B variants when compared with those with C variants. Infections with A and C variants were detected in 50 and 41 Caucasian women and in 15 and 23 African‐American women, respectively. The likelihood of clearance of the infection was significantly lower in African‐American women with C variants than in African‐American women with A variants (p = 0.05). There was no difference in the likelihood of clearance between A and C variants among Caucasian women. Our data indicated that infections with B variants were more likely to resolve than those with C variants. The difference in clearance of A vs. C variants in African‐Americans, but not in Caucasians, suggests a possibility of the race‐related influence in retaining the variant‐specific infection.
Nuclear EGFRvIII‐STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl‐XL promoter
Authors: Latha Khatri , Li Ming , Chumbalkar Vaibhav , Gururaj Anupama , Hwang YeoHyeon , Dakeng Sumana , Sawaya Raymond , Aldape Kenneth , Cavenee Webster K. , Bogler Oliver , Furnari Frank B. 
Published: June 2012

AbstractAberrant EGFR signaling strongly promotes glioma malignancy and treatment resistance. The most prevalent mutation, ΔEGFR/EGFRvIII, is an in‐frame deletion of the extracellular domain, which occurs in more than 25% of glioblastomas and enhances growth and survival of tumor cells. Paradoxically, the signaling of the potent oncogene ΔEGFR is of low intensity, raising the question of whether it exhibits preferential signaling to key downstream targets. We have observed levels of phosphorylation of STAT5 at position Y699 in cells expressing ΔEGFR that are similar or higher than in cells that overexpress EGFR and are acutely stimulated with EGF, prompting us to investigate the role of STAT5 activation in glioblastoma. Here, we show that in human glioblastoma samples, pSTAT5 levels correlated positively with EGFR expression and were associated with reduced survival. Interestingly, the activation of STAT5b downstream of ΔEGFR was dependent on SFKs, while the signal from acutely EGF‐stimulated EGFR to STAT5b involved other kinases. Phosphorylated STAT5b and ΔEGFR associated in the nucleus, bound DNA and were found on promoters known to be regulated by STAT5 including that of the Aurora A gene. ΔEGFR cooperated with STAT5b to regulate the Bcl‐XL promoter and knockdown of STAT5b suppressed anchorage independent growth, reduced the levels of Bcl‐XL and sensitized glioblastoma cells to cisplatin. Together these results delineate a novel association of nuclear ΔEGFR with STAT5b, which promotes oncogenesis and treatment resistance in glioblastoma by direct regulation of anti‐apoptotic gene, Bcl‐XL.
MiR‐17‐5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells
Authors: Wei Qian , Li Yi‐Xuan , Liu Min , Li Xin , Tang Hua 
Published: June 2012

AbstractMicroRNAs are a class of small endogenous noncoding RNAs that function as post‐transcriptional regulators. Tumor protein p53‐induced nuclear protein 1 (TP53INP1) is a p53 target gene and is a major player in the stress response. Here, we identified TP53INP1 as a target of miR‐17‐5p. miR‐17‐5p suppressed cell growth and promoted apoptosis of cervical cancer cells, whereas the effects of TP53INP1 were opposite, and ectopic expression of TP53INP1 counteracted the suppression of cell growth caused by miR‐17‐5p. The same correlations between miR‐17‐5p and TP53INP1 were observed in cervical cancer tissues. Together, these results indicated that miR‐17‐5p functions as a tumor suppressor in cervical cancer cells by targeting TP53INP1. © 2012 IUBMB IUBMB Life, 64(8): 697–704, 2012
Dietary Coleus forskohlii extract generates dose‐related hepatotoxicity in mice
Authors: Virgona Nantiga , Taki Yuko , Yamada Shizuo , Umegaki Keizo 
Published: June 2012

ABSTRACTColeus forskohlii root extract (CFE) represented by its bioactive constituent ’forskolin‘ is popularly used as a natural weight‐lowering product, but the association of its use with liver‐related risks is very limited. In the present study, the effect of standardized CFE with 10% forskolin on liver function of mice was examined. Mice were given 0–5% CFE in an AIN93G‐based diet for 3–5 weeks. Food intake, body weights, relative organ weights and liver marker enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)] combined with histophatological analysis were assessed. CFE (0–0.5%) only had minimal effects on food intake and body weight whereas a significant difference was observed in mice receiving the highest dose (5% CFE). The extract 0.05–5% dose‐dependently decreased visceral fat weight by between 16% and 63%, and a dose‐dependent several folds increase was observed in liver weights and plasma AST, ALT and ALP activities with quick onset apparent after only 1 week of 0.5% CFE intake. The hepatic effect persisted throughout the 3‐weeks course but was restored towards normalization within 1 week after withdrawal of treatment. Liver histology of mice fed 0.5% CFE for 3 weeks showed hepatocyte hypertrophy and fat deposition. In contrast, none of the hepatic responses measured were altered when mice were given a diet containing pure forskolin alone at the dose corresponding to its content in 0.5% CFE. The present study clearly indicated that forskolin was not involved in the CFE‐induced hepatotoxicity and was caused by other unidentified constituents in CFE which warrants further studies. Copyright © 2012 John Wiley & Sons, Ltd.